Michael W. Freeman

Michael W. Freeman joined Raymond James Ltd. in 2019 and was promoted in 2024 to lead Canadian coverage of healthcare services, biotechnology, medical technology, and pharmaceuticals. Prior to joining Raymond James Ltd., he was an equity research associate covering healthcare and biotechnology at a boutique investment bank in Toronto, and was a process engineer at WSP Global, an international strategic advisory and engineering services firm. He holds an MASc in chemical engineering focused on the development of nanomedicines for cancer treatment from the University of Toronto and a BASc in chemical engineering focused on biological engineering and process chemistry from Queen’s University.